First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed.

1. Genomic insights into multidrug-resistant bacteria: Emergence ofVirulence · 2026
   Article
2. Development of simplex and multiplex immunochromatographic assays for rapid detection of GES-, PER-, and VEB-producing gram-negative bacteria.Microbiology spectrum · 2026
   Article
3. Global genomic epidemiology ofMicrobial genomics · 2024
   Article
4. A panel of diverseMicrobial genomics · 2023
   Article
5. Novel Insights intoMicrobiology spectrum · 2022
   Article
6. First Detection of GES-5-ProducingMicroorganisms · 2020
   Article
7. Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.Frontiers in medicine · 2020
   Review
8. Antibiogram and Genetic Characterization of Carbapenem-Resistant Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections.Infection and drug resistance · 2020
   Article
9. Detection of β-lactamase encoding genes in feces, soil and water from a Brazilian pig farm.Environmental monitoring and assessment · 2018
   Article
10. ESBL-producingFood safety (Tokyo, Japan) · 2017
    Review
11. Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.Antimicrobial agents and chemotherapy · 2017
    Article
12. Structural and Functional Aspects of Class A Carbapenemases.Current drug targets · 2016
    Review
13. Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods.Frontiers in microbiology · 2016
    Review
14. Fast and Accurate Large-Scale Detection of β-Lactamase Genes Conferring Antibiotic Resistance.Antimicrobial agents and chemotherapy · 2015
    Article
15. Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates Using the VITEK AST-N202 Card.Infection & chemotherapy · 2015
    Article
16. Kinetic and structural requirements for carbapenemase activity in GES-type β-lactamases.Biochemistry · 2015
    Article
17. A report on the presence of GES-5 extended spectrum beta-lactamase producing Pseudomonas aeruginosa associated with urinary tract infection from north-east India.The Indian journal of medical research · 2014
    Article
18. Detection of bla(GES-5) in carbapenem-resistant Kluyvera intermedia isolates recovered from the hospital environment.Antimicrobial agents and chemotherapy · 2014
    Article
19. "Stormy waters ahead": global emergence of carbapenemases.Frontiers in microbiology · 2013
    Article
20. Molecular characterization of β-lactam-resistant Escherichia coli isolated from Fu River, China.World journal of microbiology & biotechnology · 2012
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as